Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Bitget App

Trade smarter

Bitget

News

Markets

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Bitget-RWA2025/11/23 20:30

By:Bitget-RWA

- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution

Swiss pharmaceutical leader

Novartis AG

(NOVN.SW) has updated its medium-term revenue outlook,

projecting annual sales growth of 5% to 6% in constant currency through 2030

, fueled by higher anticipated peak sales for its flagship oncology treatments Kisqali and Scemblix. This revised forecast,

shared at a management meeting in London

, signals the company’s optimism in its product lineup even as major drugs like Cosentyx and Entresto approach patent expiration. CEO Vas Narasimhan highlighted the robustness of Novartis’s development pipeline, which features eight lower-risk drugs each with peak sales potential between $3 billion and $10 billion, along with more than 30 promising candidates in advanced development.

Experts remain split on whether Novartis can maintain this growth trajectory. While

Stefan Schneider of Vontobel commended

the company for reliably meeting its goals and raising its peak sales forecasts for Kisqali (now $10 billion) and Scemblix ($4 billion), J.P. Morgan pointed to challenges from patent cliffs and uncertainties in the drug pipeline after 2030. The bank

observed that reaching $72.4 billion in sales by 2030

will depend on strong clinical trial outcomes and regulatory green lights. Following the news, shares of

Novartis

gained 0.5%,

bringing the stock’s year-to-date increase to 16%

Pre-market trading in the pharmaceutical industry was mixed.

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats image 0

Exact Sciences jumped more than 17%

after Abbott Laboratories announced plans to buy the liquid biopsy company for $105 per share. At the same time, Super Micro Computer (SMCI) rose over 5% after unveiling new GPU systems that use AMD’s Instinct MI355X chips.

Samsung Biologics, a contract development and manufacturing organization (CDMO) based in South Korea, is set for further expansion after spinning off its biosimilar business.

Analyst Yisoo Jeong from IBK Securities believes

that this move could help attract additional CDMO deals by easing clients’ worries about their intellectual property being exposed to Samsung’s own drug development. According to the analyst, the change

has led to a 71% upward revision

in the company’s valuation.

Novartis’s new outlook also highlighted the significance of its upcoming milestones. The company anticipates more than 15 pivotal readouts over the next two years,

including results from advanced-stage cancer and rare disease studies

. Still,

J.P. Morgan warned that pricing challenges

for Kisqali in the U.S. could become an obstacle, especially if the drug is subject to Medicare price negotiations.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

- Ethereum faces critical support at $2,873, with RSI near oversold levels signaling potential deeper correction or trend reversal above $3,554 EMA. - Altcoin ETFs (XRP, SOL) attract $500M inflows vs. $4.2B outflows from BTC/ETH ETFs, reflecting shifting institutional/retail capital allocation. - Coinbase's $1M ETH-backed USDC loans and $73.6B Q3 DeFi credit volume highlight Ethereum's role in onchain liquidity solutions. - Arbitrum challenges Ethereum's RISC-V proposal, advocating WebAssembly for smart co

Bitget-RWA•2025/11/23 22:16

Ethereum News Today: Ethereum Faces a Pivotal Moment: Will the Rise of Altcoin ETFs Ignite a Bullish Recovery?

Dogecoin News Today: Institutional ETF Adoption Signals Dogecoin's Transition from Meme Status to Mainstream Acceptance

- Dogecoin's 40/30/30 temperature metric crossed a critical threshold, signaling potential market dynamics shifts after months of stagnation. - The first U.S. leveraged Dogecoin ETF (TXXD) launched by 21Shares marks institutional adoption, enhancing liquidity and mainstream credibility. - Historical patterns show temperature spikes precede bull markets, though current macroeconomic uncertainty complicates trend interpretation. - Analysts view the composite metric as a systemic shift indicator, not a direct

Bitget-RWA•2025/11/23 22:02

Dogecoin News Today: Institutional ETF Adoption Signals Dogecoin's Transition from Meme Status to Mainstream Acceptance

Bitcoin News Update: Bitcoin ETFs See $3.55B Outflow Amid Death Cross and Waning Rate Optimism Trigger Sell-Off

- U.S. spot Bitcoin ETFs lost $3.55B in November 2025, with BlackRock's IBIT accounting for 63% of outflows amid crypto market declines. - Bitcoin's drop below $90,000 triggered stop-loss orders and leveraged liquidations, with $903M in single-day outflows on Nov. 14. - Analysts cite bearish technical signals, fading Fed rate-cut hopes, and a fourth "death cross" as key drivers of institutional selling pressure. - Ethereum ETPs lost $74.2M while Solana ETFs gained $26.2M, reflecting divergent crypto asset

Bitget-RWA•2025/11/23 22:02

Dogecoin News Update: Is Dogecoin Facing Collapse or a New Beginning? ETF Developments and Rising Burn Rate Challenge the Latest Downturn

- Dogecoin (DOGE) and Shiba Inu (SHIB) fell 9.5% and 10.5% respectively, but Grayscale's upcoming ETF and SHIB's 23,864% burn rate surge signal potential recovery. - 21Shares launched a 2x leveraged DOGE ETF, reflecting growing institutional interest in meme coins, while SHIB's ecosystem gains credibility with Japan's regulatory approval. - Analysts highlight ETF catalysts and cultural momentum for DOGE, but warn of technical risks as prices near $0.15 support levels.

Bitget-RWA•2025/11/23 22:02